Last $3.86 USD
Change Today 0.00 / 0.00%
Volume 0.0
VVUS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for vivus inc (VVUS)

VIVUS Inc. may have more financial risk than other companies in the Pharmaceuticals industry as it is one of the most highly leveraged. Its Debt to Total Capital ratio stands at 58.15%. VIVUS Inc. may have more financial risk than other companies in the Pharmaceuticals industry. It remains one of the most highly leveraged, despite its Debt to Total Capital ratio shrinking to 58.15% over the last fiscal year. However, an examination of near-term assets and liabilities shows that there are enough liquid assets to satisfy current obligations. Accounts Receivable are among the industry's worst with 33.74 days worth of sales outstanding. This implies that revenues are not being collected in an efficient manner. Last, VIVUS Inc. is among the most efficient in its industry at managing inventories, with only 893.04 days of its Cost of Goods Sold tied up in inventory.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Restated
Dec 31
2011
Restated
Dec 31
2012
Restated
Dec 31
2013
4 Year
Trend
Assets    
Cash and Equivalents37.239.658.6103.3
Short-Term Investments102.0107.3156.0240.0
TOTAL CASH AND SHORT TERM INVESTMENTS139.2146.8214.6343.3
Accounts Receivable----2.812.2
Other Receivables--0.7----
TOTAL RECEIVABLES--0.72.812.2
Inventory3.23.125.448.5
Prepaid Expenses1.61.119.213.1
Other Current Assets0.0----6.8
TOTAL CURRENT ASSETS144.1151.7261.9423.9
Gross Property Plant and Equipment1.31.53.44.2
Accumulated Depreciation-1.1-1.2-1.4-2.3
NET PROPERTY PLANT AND EQUIPMENT0.20.32.02.0
Deferred Charges, Long Term------4.6
Other Long-Term Assets----0.31.3
TOTAL ASSETS144.3152.1264.1431.8
    
LIABILITIES & EQUITY    
Accounts Payable2.42.925.410.8
Accrued Expenses6.46.413.819.4
Other Current Liabilities, Total3.51.60.94.6
Unearned Revenue, Current----1.217.3
TOTAL CURRENT LIABILITIES12.311.041.252.0
Long-Term Debt------213.1
Unearned Revenue, Non-Current------10.4
Other Non-Current Liabilities------3.0
TOTAL LIABILITIES12.311.041.2278.4
Common Stock0.10.10.10.1
Additional Paid in Capital432.0487.2708.9813.8
Retained Earnings-300.1-346.3-486.1-660.6
Comprehensive Income and Other0.00.00.00.1
TOTAL COMMON EQUITY132.0141.1222.9153.4
TOTAL EQUITY132.0141.1222.9153.4
TOTAL LIABILITIES AND EQUITY144.3152.1264.1431.8
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $3.86 USD 0.00

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.19 USD 0.00
GlaxoSmithKline Consumer Healthcare Ltd 5,575 INR -62.25
GlaxoSmithKline PLC 1,416 GBp +2.50
Roche Holding AG SFr.284.10 CHF +1.00
View Industry Companies
 

Industry Analysis

VVUS

Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.